Clinical trial · Interventional
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
UARK 99-016, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Multiple Myeloma and Poor Hematopoietic Stem Cell Reserve
NCT00083408CI-TRIAL-00003637completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate is in controlling multiple myeloma and to study any side effects that may be experienced.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pamidronate | Drug | — | UNRESOLVED |
| Thalidomide | Drug | Thalidomide | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the effectiveness of combination treatment with Thalidomide and Pamidronate in patients with refractory myeloma and poor hematopoietic stem cell reserve. Effectiveness will be based on the estimate of the objective response rate (CR + PR).
Secondary outcomes (1)
- measure
- To compare the effect of these agents on disease parameters, specifically on time to disease progression and overall survival.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have a diagnosis of Multiple myeloma with poor hematopoietic reserve (platelet count \<100,000 OR inability to collect adequate PBSC to support autologous transplant (4X106 CD34+cells/kg OR WBC \<2,000) * Patients must not be eligible for UARK 98-035 * Patients must be at least 6 weeks beyond previous chemotherapy * All patients must be informed of the investigational nature of this study and must sign a written informed consent in accordance with UAMS Human Research Advisory Committee and federal guidelines Exclusion Criteria: * Prior bisphosphonate therapy within 30 days prior to study entry * Serum creatinine \> 5 mg/dl, ascites, or serum direct bilirubin \> 2.5 mg/dl * Prior plicamycin or calcitonin within 2 weeks of study entry * Severe cardiac disease, unstable thyroid disease, or epilepsy
References
Publications (0)
Data not yet available
No reference posted for this study.